Economic evaluation within a factorialdesign randomised controlled trial of exercise, manual therapy, or both interventions for osteoarthritis of the hip or knee: Study protocol

BMJ Open

Volumn 1, Issue 1, 2011, Pages

  Pinto, Daniel ^a,b   Robertson, M Clare ^c   Hansen, Paul ^a   Abbott, J Haxby ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960020640     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000136     Document Type: Article

References (44)

1. Bijlsma JWJ, Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Pract Res Clin Rheumatol 2007;21:59-76. (Pubitemid 46351947)
2. Dawson J, Linsell L, Zondervan K, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) 2004;43:497-504. (Pubitemid 38489368)
3. A Portrait of Health: Key Results of the 2006/2007 New Zealand Health Survey. Wellington: Ministry of Health, 2008.
4. Tobias M. The Burden of Disease and Injury in New Zealand. Wellington: Ministry of Health, 2001.
5. New Zealand Orthopaedic Association. National joint registry, ten year report (January 1999 to December 2008). In: Rothwell A, Hobbs T, Frampton C, eds. Canterbury: The New Zealand Joint Registry. 2009.
6. Christchuch: Access Economics. The Economic Cost of Arthritis in New Zealand. Report for Arthritis New Zealand. Canterbury District Health Board, Ltd, 2005.
7. Older New Zealanders 65 and Beyond. Wellington: Statistics New Zealand, 2004.
8. Osteoarthritis: the Care and Management of Osteoarthritis in Adults. London: National Institute for Health and Clinical Excellence, 2008.
9. Akesson K, Woolf AD. How to develop strategies for improving musculoskeletal health. Best Pract Res Clin Rheumatol 2007;21:5-25. (Pubitemid 46351952)
10. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81. (Pubitemid 40559291)
11. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62. (Pubitemid 351222155)
12. Chang RW, Pellissier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996;275:858-65. (Pubitemid 26087223)
13. Losina E, Walensky RP, Kessler CL, et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med 2009;169:1113-22.
14. Ratcliffe J, Buxton M, McGarry T, et al. Patients' preferences for characteristics associated with treatments for osteoarthritis. Rheumatology (Oxford) 2004;43:337-45. (Pubitemid 38313184)
15. Hoeksma HL, Dekker J, Ronday HK, et al. Comparison of manual therapy and exercise therapy in osteoarthritis of the hip: a randomized clinical trial. Arthritis Rheum 2004;51:722-9. (Pubitemid 39372030)
16. Deyle GD, Henderson NE, Matekel RL, et al. Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial. Ann Intern Med 2000;132:173-81. (Pubitemid 30064916)
17. Deyle GD, Allison SC, Matekel RL, et al. Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys Ther 2005;85:1301-17. (Pubitemid 41746276)
18. Abbott JH, Robertson MC, McKenzie JE, et al. Exercise therapy, manual therapy, or both, for osteoarthritis of the hip or knee: a factorial randomised controlled trial protocol. Trials 2009;10:11.
19. Altman DG, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthitis Rheum 1986;29:1039-49.
20. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthitis Rheum 1991;34:505-14.
21. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-effectiveness In Health and Medicine. New York: Oxford University Press, 1996.
22. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economics Evaluation of Health Care Programmes. 3rd edn. New York: Oxford University Press, 2005.
23. Drummond M, Maetzel A, Gabriel S, et al. Towards a reference case for use in future economic evaluations of interventions in osteoarthritis. J Rheumatol Suppl 2003;68:26-30. (Pubitemid 37549319)
24. Brazier J, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9. (Pubitemid 39456916)
25. Ramsey S, Willke R, Briggs A, et al. (2005) Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value in Health 2005;8:521-33. (Pubitemid 41727304)
26. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96. (Pubitemid 40723857)
27. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99. (Pubitemid 38594267)
28. Goodacre S, McCabe C. An introduction to economic evaluation. Emerg Med J 2002;19:198-201. (Pubitemid 34601140)
29. Drummond MF, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-71. (Pubitemid 40656544)
30. Pinto D, Robertson MC, Hansen P, et al. Good agreement between questionnaire and administrative databases for health care use and costs in patients with osteoarthritis. BMC Med Res Methodol 2011;11:45. [Epub ahead of print].
31. Cochrane T, Davey RC, Matthes Edwards SM. Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis. Health Technol Assess 2005;9:iii-iv, ix-xi, 1-114.
32. Lanes SK, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthitis Rheum 1997;40:1475-81. (Pubitemid 27430959)
33. Mittendorf T, Merkesdal S, Huelsemann JL, et al. Implementing standardized cost categories within economic evaluations in musculoskeletal diseases. Eur J Health Econ 2003;4:43-9. (Pubitemid 36457056)
34. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev 2006;63:217-35. (Pubitemid 43344151)
35. Lagan J, Scott B. The New Zealand Pharmaceutical Schedule. Wellington: Pharmaceutical Management Agency, 2009:1-224.
36. Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 2005;23:105-11. (Pubitemid 40460650)
37. van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010;69:i89-91.
38. Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis 2004;63:408-14. (Pubitemid 38453307)
39. Hay JW. Using pharmacoeconomics to value pharmacotherapy. Clin Pharmacol Ther 2008;84:197-200.
40. who.int/en/. World Health Organization (WHO) WHO. Threshold values for intervention cost-effectiveness by region. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Threshold values for intervention cost-effectiveness by region [1 screen]. c2005-2010. Available from: http://www.who.int/choice/costs/ CER-levels/en/index.html (accessed 10 Dec. 2010).
41. Briggs AH, Wonderling DE, Mooney CZ. Pulling costeffectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40. (Pubitemid 27384638)
42. Barber J, Thompson S. Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ 1998;317:1195-200. (Pubitemid 28488509)
43. Glick HA, Doshi JA, Sonnad SS, et al. Economic Evaluation in Clinical Trials. Oxford: Oxford University Press, 2007.
44. Statistics New Zealand. Household Expenditure for Group and Subgroup by Broad Region: Health Category: Statistics. Wellington: Statistics New Zealand, 2011.